Company Overview

Azenta, Inc. is a life sciences and biotechnology infrastructure company focused on sample management, cold-chain logistics, genomic services, and laboratory automation solutions. The company operates primarily within the life sciences tools and services industry, serving pharmaceutical companies, biotechnology firms, academic research institutions, healthcare organizations, and clinical laboratories. Azenta’s business model centers on enabling research, drug discovery, biologics development, and precision medicine workflows through integrated laboratory services and automated sample management technologies.

The company’s principal revenue drivers include its Sample Management Solutions and Multiomics businesses, which provide biorepository services, automated storage systems, genomic sequencing, synthetic biology support, and cold-chain logistics capabilities. Azenta evolved from Brooks Automation, Inc., a semiconductor automation company founded in 1978, and transitioned strategically toward life sciences over the past decade through acquisitions and divestitures. Following the sale of its semiconductor automation business in 2022, the company rebranded as Azenta to reflect its focus on life sciences infrastructure and research enablement. Public filings and investor materials consistently identify the company’s strategic differentiation as its integrated combination of automated sample storage, biologic sample handling, and genomic analysis capabilities.

Business Operations

Azenta organizes its operations primarily through two core business areas: Sample Management Solutions and Multiomics. The Sample Management Solutions segment provides automated ultra-low temperature storage systems, sample repositories, consumables, software, and logistics services designed to preserve and manage biological samples for pharmaceutical and biotechnology customers. This segment also includes cold-chain transportation and biologic material handling capabilities supporting clinical trials and drug development programs. The company generates recurring revenue through long-term sample storage contracts, logistics services, and laboratory workflow support.

The Multiomics segment delivers genomic sequencing, gene synthesis, bioinformatics, and related laboratory services used in drug discovery, cell and gene therapy research, and clinical development. Azenta operates laboratory and logistics facilities across North America, Europe, and Asia and maintains relationships with major pharmaceutical and biotechnology firms globally. The company controls proprietary automation technologies for sample storage and retrieval and operates specialized cryogenic and ultra-low temperature infrastructure. Public disclosures also identify strategic operational capabilities through subsidiaries and acquired businesses including GENEWIZ, B Medical Systems, and related genomics and biologic sample management operations.

Strategic Position & Investments

Azenta’s strategic direction has centered on building a fully integrated life sciences infrastructure platform focused on biologic sample management and genomic services. The company has emphasized expansion into high-growth areas such as cell and gene therapy support, precision medicine, biobanking, and multiomics research. Management has consistently identified recurring service revenue, laboratory automation adoption, and biologic sample complexity as long-term growth drivers in investor presentations and annual reports.

The company has pursued this strategy through acquisitions and targeted investments. Notable transactions include the acquisition of GENEWIZ, which expanded Azenta’s genomic sequencing and synthesis capabilities, and B Medical Systems, which strengthened its cold-chain and vaccine storage infrastructure. Azenta has also invested in advanced automated storage systems and laboratory informatics platforms intended to support pharmaceutical R&D workflows and decentralized clinical research operations. Available public information indicates continued investment in scalable genomic services, cryogenic technologies, and biologic logistics infrastructure, though some future expansion plans remain subject to changing market conditions and customer demand.

Geographic Footprint

Azenta is headquartered in Burlington, Massachusetts, United States, and maintains operations across North America, Europe, and Asia-Pacific. The company operates laboratory, logistics, and sample storage facilities in multiple countries, supporting global pharmaceutical and biotechnology research programs. Its customer base includes multinational biopharmaceutical firms, academic institutions, and healthcare organizations requiring cross-border biologic sample transport and genomic analysis capabilities.

The company maintains a particularly strong presence in the United States, Europe, China, Singapore, and other major biotechnology and pharmaceutical research markets. Through its cold-chain and genomic operations, Azenta supports international clinical trials and research collaborations involving highly temperature-sensitive biologic materials. Public company disclosures indicate that international operations contribute a substantial portion of overall revenue, reflecting the global nature of biopharmaceutical research and sample management demand.

Leadership & Governance

Azenta’s leadership team oversees the company’s transition from industrial automation into a focused life sciences infrastructure business. Management has emphasized operational discipline, recurring revenue growth, and expansion into biologics and genomics-related services. The company operates under a board-governed structure typical of publicly traded U.S. life sciences companies and files regular disclosures through the SEC including annual reports and proxy statements.

Key executives identified in recent public filings and investor communications include:

• John F. Marotta – President and Chief Executive Officer
• Lindon Robertson – Executive Vice President and Chief Financial Officer
• Karen Dawes – Senior Vice President, Chief Human Resources Officer
• David Wang – Senior Vice President and President, Sample Management Solutions
• Ginger Zhou – Senior Vice President and President, Multiomics

The company’s leadership strategy has consistently emphasized long-term investment in life sciences infrastructure, operational integration across acquired businesses, and expansion of global laboratory and biologic sample management capabilities.